Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
AssigneeTheravance Biopharma R&D IP, LLC
InventorsRobert Murray McKinnell, Erik Fenster, Tom M. Lam, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
Life of this patent
Estimating the term…
Abstract
The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
Claims16
A pharmaceutical composition comprising a compound of formula:
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier.
A pharmaceutical composition comprising a compound of formula:
- and a pharmaceutically-acceptable carrier.
A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a crystalline form of the compound of formula:
- wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at 2θ values of 9.67±0.20, 11.61±0.20, 17.61±0.20, 18.88±0.20, and 23.33±0.20.
Dependencies are inferred from the claim text.